Avantor (NYSE:AVTR) Price Target Cut to $25.00 by Analysts at Wells Fargo & Company

Avantor (NYSE:AVTR) had its price objective reduced by Wells Fargo & Company from $28.00 to $25.00 in a research note released on Monday morning,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock.

Other analysts have also recently issued research reports about the stock. UBS Group reissued a “neutral” rating and set a $25.00 price objective (down previously from $29.00) on shares of Avantor in a report on Friday, January 17th. Robert W. Baird cut their price target on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th. Raymond James decreased their price objective on shares of Avantor from $29.00 to $26.00 and set an “outperform” rating for the company in a research note on Tuesday, January 21st. Stifel Nicolaus dropped their price objective on Avantor from $28.00 to $26.00 and set a “buy” rating on the stock in a report on Monday. Finally, Barclays reduced their target price on Avantor from $26.00 to $23.00 and set an “overweight” rating for the company in a report on Monday. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $26.15.

Avantor Price Performance

AVTR opened at $19.00 on Monday. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84. The firm has a market cap of $12.93 billion, a price-to-earnings ratio of 41.30, a PEG ratio of 3.87 and a beta of 1.28. The stock’s 50-day moving average price is $21.73 and its 200 day moving average price is $23.47. Avantor has a 12-month low of $18.49 and a 12-month high of $28.00.

Avantor (NYSE:AVTR) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same period in the prior year, the company earned $0.22 earnings per share. As a group, sell-side analysts expect that Avantor will post 0.98 earnings per share for the current year.

Institutional Investors Weigh In On Avantor

Hedge funds and other institutional investors have recently modified their holdings of the stock. Louisiana State Employees Retirement System lifted its holdings in shares of Avantor by 0.3% in the fourth quarter. Louisiana State Employees Retirement System now owns 188,900 shares of the company’s stock valued at $3,980,000 after purchasing an additional 500 shares in the last quarter. Hantz Financial Services Inc. raised its position in shares of Avantor by 2.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 24,900 shares of the company’s stock worth $644,000 after purchasing an additional 503 shares during the last quarter. Blue Trust Inc. lifted its stake in Avantor by 6.9% in the 4th quarter. Blue Trust Inc. now owns 8,069 shares of the company’s stock valued at $170,000 after buying an additional 522 shares in the last quarter. Pacer Advisors Inc. grew its holdings in Avantor by 0.5% during the 4th quarter. Pacer Advisors Inc. now owns 99,825 shares of the company’s stock valued at $2,103,000 after buying an additional 542 shares during the last quarter. Finally, Veracity Capital LLC increased its position in Avantor by 1.0% during the third quarter. Veracity Capital LLC now owns 52,359 shares of the company’s stock worth $1,355,000 after buying an additional 543 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.